Sertraline Hydrochloride: Package Insert and Label Information (Page 4 of 8)
ADVERSE REACTIONS
During its premarketing assessment, multiple doses of sertraline hydrochloride were administered to over 4000 adult subjects as of February 18, 2000. The conditions and duration of exposure to sertraline hydrochloride varied greatly, and included (in overlapping categories) clinical pharmacology studies, open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies, and studies for multiple indications, including major depressive disorder and PMDD.
Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.
In the tabulations that follow, a World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the over 4000 adult individuals exposed to multiple doses of sertraline hydrochloride who experienced a treatment-emergent adverse event of the type cited on at least one occasion while receiving sertraline hydrochloride. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that events reported during therapy were not necessarily caused by it.
The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.
Incidence in Placebo-Controlled Trials – Table 2 enumerates the most common treatment-emergent adverse events associated with the use of Sertraline hydrochloride (incidence of at least 5% for Sertraline hydrochloride and at least twice that for placebo within at least one of the indications) for the treatment of adult patients with major depressive disorder/other*, OCD, panic disorder, PTSD, PMDD and social anxiety disorder in placebo-controlled clinical trials. Most patients in major depressive disorder/other*, OCD, panic disorder, PTSD and social anxiety disorder studies received doses of 50 to 200 mg/day. Patients in the PMDD study with daily dosing throughout the menstrual cycle received doses of 50 to 150 mg/day, and in the PMDD study with dosing during the luteal phase of the menstrual cycle received doses of 50 to 100 mg/day. Table 3 enumerates treatment-emergent adverse events that occurred in 2% or more of adult patients treated with Sertraline hydrochloride and with incidence greater than placebo who participated in controlled clinical trials comparing Sertraline hydrochloride with placebo in the treatment of major depressive disorder/other*, OCD, panic disorder, PTSD, PMDD and social anxiety disorder. Table 3 provides combined data for the pool of studies that are provided separately by indication in Table 2.
Adverse Reactions II
| *Major depressive disorder and other premarketing controlled trials. | ||||||||
| (1) Primarily ejaculatory delay. Denominator used was for male patients only (N=271 sertraline hydrochloride major depressive disorder/other*; N=271 placebo major depressive disorder/other*; N=296 sertraline hydrochloride OCD; N=219 placebo OCD; N=216 sertraline hydrochloride panic disorder; N=134 placebo panic disorder; N=130 sertraline hydrochloride PTSD; N=149 placebo PTSD; No male patients in PMDD studies; N=205 sertraline hydrochloride social anxiety disorder; N=153 placebo social anxiety disorder). | ||||||||
| (2) The luteal phase and daily dosing PMDD trials were not designed for making direct comparisons between the two dosing regimens. Therefore, a comparison between the two dosing regimens of the PMDD trials of incidence rates shown in Table 2 should be avoided. | ||||||||
| Percentage of Patients Reporting Event | ||||||||
| Major Depressive Disorder/Other* | OCD | Panic Disorder | PTSD | |||||
| Body System/Adverse Event | Sertraline (N=861) | Placebo (N=853) | Sertraline (N=533) | Placebo (N=373) | Sertraline (N=430) | Placebo (N=275) | Sertraline (N=374) | Placebo (N=376) |
| Autonomic Nervous System Disorders | ||||||||
| Ejaculation Failure (1) | 7 | <1 | 17 | 2 | 19 | 1 | 11 | 1 |
| Mouth Dry | 16 | 9 | 14 | 9 | 15 | 10 | 11 | 6 |
| Sweating Increased | 8 | 3 | 6 | 1 | 5 | 1 | 4 | 2 |
| Center. & Peripheral. Nervous. System Disorders | ||||||||
| Somnolence | 13 | 6 | 15 | 8 | 15 | 9 | 13 | 9 |
| Tremor | 11 | 3 | 8 | 1 | 5 | 1 | 5 | 1 |
| Dizziness | 12 | 7 | 17 | 9 | 10 | 10 | 8 | 5 |
| General | ||||||||
| Fatigue | 11 | 8 | 14 | 10 | 11 | 6 | 10 | 5 |
| Pain | 1 | 2 | 3 | 1 | 3 | 3 | 4 | 6 |
| Malaise | <1 | 1 | 1 | 1 | 7 | 14 | 10 | 10 |
| Gastrointestinal Disorders | ||||||||
| Abdominal Pain | 2 | 2 | 5 | 5 | 6 | 7 | 6 | 5 |
| Anorexia | 3 | 2 | 11 | 2 | 7 | 2 | 8 | 2 |
| Constipation | 8 | 6 | 6 | 4 | 7 | 3 | 3 | 3 |
| Diarrhea/Loose Stools | 18 | 9 | 24 | 10 | 20 | 9 | 24 | 15 |
| Dyspepsia | 6 | 3 | 10 | 4 | 10 | 8 | 6 | 6 |
| Nausea | 26 | 12 | 30 | 11 | 29 | 18 | 21 | 11 |
| Psychiatric Disorders | ||||||||
| Agitation | 6 | 4 | 6 | 3 | 6 | 2 | 5 | 5 |
| Insomnia | 16 | 9 | 28 | 12 | 25 | 18 | 20 | 11 |
| Libido Decreased | 1 | <1 | 11 | 2 | 7 | 1 | 7 | 2 |
| Percentage of Patients Reporting Event | ||||||||
| PMDD Daily Dosing |
| Social Anxiety Disorder | ||||||
| Body System/Adverse Event | Sertraline (N=121) | Placebo (N=122) | Sertraline (N=136) | Placebo (N=127) | Sertraline (N=344) | Placebo (N=268) | ||
| Autonomic Nervous System Disorders | ||||||||
| Ejaculation Failure (1) | N/A | N/A | N/A | N/A | 14 | – | ||
| Mouth Dry | 6 | 3 | 10 | 3 | 12 | 4 | ||
| Sweating Increased | 6 | <1 | 3 | 0 | 11 | 2 | ||
| Center. & Peripheral. Nervous. System Disorders | ||||||||
| Somnolence | 7 | <1 | 2 | 0 | 9 | 6 | ||
| Tremor | 2 | 0 | <1 | <1 | 9 | 3 | ||
| Dizziness | 6 | 3 | 7 | 5 | 14 | 6 | ||
| General | ||||||||
| Fatigue | 16 | 7 | 10 | <1 | 12 | 6 | ||
| Pain | 6 | <1 | 3 | 2 | 1 | 3 | ||
| Malaise | 9 | 5 | 7 | 5 | 8 | 3 | ||
| Gastrointestinal Disorders | ||||||||
| Abdominal Pain | 7 | <1 | 3 | 3 | 5 | 5 | ||
| Anorexia | 3 | 2 | 5 | 0 | 6 | 3 | ||
| Constipation | 2 | 3 | 1 | 2 | 5 | 3 | ||
| Diarrhea/Loose Stools | 13 | 3 | 13 | 7 | 21 | 8 | ||
| Dyspepsia | 7 | 2 | 7 | 3 | 13 | 5 | ||
| Nausea | 23 | 9 | 13 | 3 | 22 | 8 | ||
| Psychiatric Disorders | ||||||||
| Agitation | 2 | <1 | 1 | 0 | 4 | 2 | ||
| Insomnia | 17 | 11 | 12 | 10 | 25 | 10 | ||
| Libido Decreased | 11 | 2 | 4 | 2 | 9 | 3 | ||
| (1) Primarily ejaculatory delay. Denominator used was for male patients only (N=1118 Sertraline hydrochloride; N=926 placebo). | |||||||||||
| *Major depressive disorder and other premarketing controlled trials. | |||||||||||
| **Included are events reported by at least 2% of patients taking Sertraline hydrochloride except the following events, which had an incidence on placebo greater than or equal to Sertraline hydrochloride: abdominal pain, back pain, flatulence, malaise, pain, pharyngitis, respiratory disorder, upper respiratory tract infection. | |||||||||||
| Body System/Adverse Event** | Sertraline (N=2799) | Placebo (N=2394) | |||||||||
| Autonomic Nervous System Disorders | |||||||||||
| Ejaculation Failure (1) | 14 | 1 | |||||||||
| Mouth Dry | 14 | 8 | |||||||||
| Sweating Increased | 7 | 2 | |||||||||
| Center. & Periph. Nerv. System Disorders | |||||||||||
| Somnolence | 13 | 7 | |||||||||
| Dizziness | 12 | 7 | |||||||||
| Headache | 25 | 23 | |||||||||
| Paresthesia | 2 | 1 | |||||||||
| Tremor | 8 | 2 | |||||||||
| Disorders of Skin and Appendages | |||||||||||
| Rash | 3 | 2 | |||||||||
| Gastrointestinal Disorders | |||||||||||
| Anorexia | 6 | 2 | |||||||||
| Constipation | 6 | 4 | |||||||||
| Diarrhea/Loose Stools | 20 | 10 | |||||||||
| Dyspepsia | 8 | 4 | |||||||||
| Nausea | 25 | 11 | |||||||||
| Vomiting | 4 | 2 | |||||||||
| General | |||||||||||
| Fatigue | 12 | 7 | |||||||||
| Psychiatric Disorders | |||||||||||
| Agitation | 5 | 3 | |||||||||
| Anxiety | 4 | 3 | |||||||||
| Insomnia | 21 | 11 | |||||||||
| Libido Decreased | 6 | 2 | |||||||||
| Nervousness | 5 | 4 | |||||||||
| Special Senses | |||||||||||
| Vision Abnormal | 3 | 2 | |||||||||
DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.
https://druginserts.com/lib/rx/meds/sertraline-hydrochloride-38/page/4/